Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Gabriela Luporini, Saraiva"'
Autor:
Annika Åstrand, Cecilia Wingren, Claire Walton, Johan Mattsson, Komal Agrawal, Madelene Lindqvist, Lina Odqvist, Björn Burmeister, Steven Eck, Glen Hughes, Gabriela Luporini Saraiva, Anna Schantz, Ioannis Psallidas, Christopher McCrae
Publikováno v:
PLoS ONE, Vol 19, Iss 5 (2024)
Externí odkaz:
https://doaj.org/article/f5cad6e900424cb396d36459f878b7bc
Autor:
Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Larisa Ramirez, Marina V. Shestakova, Iichiro Shimomura, Filip Surmont, Fengming Tang, Jiten Vora, Hirotaka Watada, Mikhail Kosiborod, the DISCOVER investigators
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 1711-1716 (2021)
Abstract Aims Heart failure (HF) is increasingly recognized as a major cause of morbidity and mortality in patients with type 2 diabetes (T2D), but the global epidemiology and treatment of HF in T2D are not well defined. This study aimed to examine t
Externí odkaz:
https://doaj.org/article/6f0d5cf6e07a4fcc98c4a0e71fee4e3d
Autor:
Marília B. Gomes, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Kamlesh Khunti, Wolfgang Rathmann, Marina V. Shestakova, Filip Surmont, Hirotaka Watada, Jesús Medina, Iichiro Shimomura, Gabriela Luporini Saraiva, Andrew Cooper, Antonio Nicolucci
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
DISCOVER is a 3-year observational study program of 15,983 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. We investigated the association between socioeconomic status and both the availability of a baseli
Externí odkaz:
https://doaj.org/article/6c2277abaa80486181f4c6426ca2717c
Autor:
Robert Wood, Lei Qin, Gabriela Luporini Saraiva, Theo Tritton, Muthiah Vaduganathan, Alex Chin, Carolyn S.P. Lam, Héctor Bueno, Elisabeth Sörstadius, Joseph Thomas
Publikováno v:
Clinical Cardiology, 44(5), 646-655. Wiley
Clinical Cardiology
Clinical Cardiology
Background Limited real-world data exist on healthcare resource utilization (HCRU) and associated costs of patients with heart failure (HF) with reduced ejection fraction (HFrEF) and preserved EF (HFpEF), including urgent HF visits, which are assumed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8615c57eeab07c4dfaae141e9bfd1b27
https://hdl.handle.net/11370/0173eb6a-1215-495e-9f84-b9db328bf3bf
https://hdl.handle.net/11370/0173eb6a-1215-495e-9f84-b9db328bf3bf
Autor:
Marília B. Gomes, Fengming Tang, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Kamlesh Khunti, Wolfgang Rathmann, Marina V. Shestakova, Filip Surmont, Hirotaka Watada, Jesús Medina, Iichiro Shimomura, Gabriela Luporini Saraiva, Andrew Cooper, Antonio Nicolucci
Publikováno v:
Frontiers in endocrinology. 13
DISCOVER is a 3-year observational study program of 15,983 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. We investigated the association between socioeconomic status and both the availability of a baseli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9f5a1fa4487107540ae4e0d1bdf523
https://pubmed.ncbi.nlm.nih.gov/35527995
https://pubmed.ncbi.nlm.nih.gov/35527995
Autor:
Niklas Hammar, Filip Surmont, Gabriela Luporini Saraiva, Hungta Chen, Andrew Cooper, Hirotaka Watada, Marina Vladimirovna Shestakova, Wolfgang Rathmann, Paul Leigh, Fabrice Bonnet, Larisa Ramirez, Discover investigators, Fengming Tang, Antonio Nicolucci, Linong Ji, Jesús Medina
Publikováno v:
Diabetes Research and Clinical Practice
Diabetes Research and Clinical Practice, Elsevier, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩
Diabetes Research and Clinical Practice, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩
Diabetes Research and Clinical Practice, Elsevier, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩
Diabetes Research and Clinical Practice, 2021, 178, pp.108947. ⟨10.1016/j.diabres.2021.108947⟩
International audience; Aims: To assess the effects of glycated haemoglobin (HbA(1c)) levels at time of glucose-lowering treatment intensification in DISCOVER, a global observational study of patients with type 2 diabetes (T2D) initiating second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c88d1b407e4b48e6f0f24bfb0890ee2
https://hal.archives-ouvertes.fr/hal-03476924
https://hal.archives-ouvertes.fr/hal-03476924
Autor:
Marilia B. Gomes, Shaukat M. Sadikot, Iichiro Shimomura, Hungta Chen, Antonio Nicolucci, Stuart Pocock, Gabriela Luporini Saraiva, Jesus Medina, Peter Fenici, Fengming Tang, Wolfgang Rathmann, Marina V. Shestakova, Javier Cid-Ruzafa, Kamlesh Khunti, Filip Surmont, Hirotaka Watada
Publikováno v:
Diabetes. 68
Background: DISCOVER is a 3-year, observational study of patients with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy in 38 countries. We assessed socioeconomic factors associated with poor glycemic control (HbA1c ≥ 9.0%) at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ec45c21464466731bc799dc14f9b908
https://doi.org/10.2337/db19-1279-p
https://doi.org/10.2337/db19-1279-p
Autor:
Bernard Charbonnel, Brenda Bongaerts, Mikhail N. Kosiborod, Suzanne V. Arnold, Peter Fenici, Wolfgang Rathmann, Marilia B. Gomes, Jesus Medina, Shaukat M. Sadikot, Stuart Pocock, Kamlesh Khunti, Hungta Chen, Iichiro Shimomura, Marina V. Shestakova, Linong Ji, Fengming Tang, Javier Cid-Ruzafa, Antonio Nicolucci, Gabriela Luporini Saraiva, Filip Surmont, Hirotaka Watada
Publikováno v:
Diabetes. 68
Background: Guidelines endorse a target HbA1c of < 7% for most people with T2D, but less stringent goals (e.g., HbA1c < 8%) and medications with a low risk of causing hypoglycemia are recommended for older patients. We examined the prevalence of pote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::901daa6e4a5a14464297636d108a8df0
https://doi.org/10.2337/db19-1448-p
https://doi.org/10.2337/db19-1448-p
Autor:
Filip Surmont, Hirotaka Watada, Marilia B. Gomes, Javier Cid-Ruzafa, Linong Ji, Stuart Pocock, Iichiro Shimomura, Bernard Charbonnel, Hungta Chen, Shaukat M. Sadikot, Suzanne V. Arnold, Peter Fenici, Mikhail N. Kosiborod, Fabrice Bonnet, Marina V. Shestakova, Kamlesh Khunti, Jesus Medina, Gabriela Luporini Saraiva, Jiten Vora, Fengming Tang
Publikováno v:
Diabetes. 68
Background: Heart failure (HF) is one of the most morbid complications of T2D, but the role of T2D in the development of HF has been under-appreciated. We assessed the incidence and prevalence of HF in a global cohort of patients with T2D. Methods: D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6e2986f5cb01a44c3ecb309cfd6122e
https://doi.org/10.2337/db19-207-lb
https://doi.org/10.2337/db19-207-lb